StockTipsArenaBeta

BUY Piramal Pharma Limited — ICICI Securities

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byICICI SecuritiesHorizon: NA (inferred 1 year)31 Jul 2026via Institutional / Brokerage Research

Entry₹196.72Inferred
Target₹245
Total upside +24.54%
Stop lossNot given
CMP₹194.99Just now
Active-0.88%+25.65%upside left 9 mo left
Follow ICICI Securities for new calls(67% target hit, 1026 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 4 other Long-term calls on PPLPHARMASee 212 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 4:05 pm IST
22 supporting11 neutral7 opposing
Supports the BUY call (22)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·21 Oct · yesterday

3 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·24 Sept · 4w ago

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·26 Aug · 2mo ago

Neutral / worth noting (11)

Q2 FY27 results scheduled — board meets 27 Oct 2026

BSE · Board Meeting·In 5 days

(opens in new tab)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (7)

Piramal Pharma received a GST order demanding Rs 4.06 crore in input tax credit plus an equivalent penalty of Rs 4.06 crore. The company plans to appeal the order and does not expect a material impact

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·29 Sept · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from ICICI Securities

Every call and its outcome